Immunotherapy for the treatment of metastatic uveal melanoma

Article Properties
  • DOI (url)
    10.36290/xon.2022.026
  • Publication Date
    2022/05/16
  • Journal
    Onkologie
  • Indian UGC (journal)
  • Refrences
    40
  • Ján Podhorec
  • Radek Lakomý
  • Alexandr Poprach
  • Igor Kiss
Cite
Podhorec, Ján, et al. “Immunotherapy for the Treatment of Metastatic Uveal Melanoma”. Onkologie, vol. 16, no. 3, 2022, pp. 130-3, https://doi.org/10.36290/xon.2022.026.
Podhorec, J., Lakomý, R., Poprach, A., & Kiss, I. (2022). Immunotherapy for the treatment of metastatic uveal melanoma. Onkologie, 16(3), 130-133. https://doi.org/10.36290/xon.2022.026
Podhorec J, Lakomý R, Poprach A, Kiss I. Immunotherapy for the treatment of metastatic uveal melanoma. Onkologie. 2022;16(3):130-3.
Refrences
Title Journal Journal Categories Citations Publication Date
Guidelines Detail 2022
now a wholly owned subsidiary of Pfizer. A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma 2020
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis

 The Oncologist
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 131 2016
10.1016/S0140-6736(96)90736-9
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas

 Science
  • Science: Science (General)
 947 2010